Mali
Tuberculosis profile
| High HIV burden |
Population  2013 15 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (1.1–2) 10 (7–13)
Mortality (HIV+TB only) 0.19 (0.16–0.22) 1.2 (1–1.4)
Prevalence  (includes HIV+TB) 14 (7.5–23) 92 (49–149)
Incidence  (includes HIV+TB) 9.2 (8.9–9.4) 60 (58–62)
Incidence (HIV+TB only) 0.63 (0.61–0.65) 4.1 (4–4.3)
Case detection, all forms (%) 63 (62–66)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
82 (4–230) 110 (1–220)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 818   183
Pulmonary, clinically diagnosed 497   0
Extrapulmonary 1 312   0
       
Total new and relapse 5 810    
Previously treated, excluding relapses 374    
Total cases notified 6 184    
Among 3 818 new cases:
53 (1%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 11 (2%) 11
Laboratory-confirmed RR-/MDR-TB cases     12
Patients started on MDR-TB treatment     18
TB/HIV 2013 Number (%)
TB patients with known HIV status 6 001 (97)
HIV-positive TB patients 414 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 414 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 414 (100)
HIV-positive people screened for TB 3 697  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 93
Previously treated cases, excluding relapse, registered in 2012 73
HIV-positive TB cases, all types, registered in 2012 53
RR-/MDR-TB cases started on second-line treatment in 2011 33
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 1.3
% Funded domestically 73%
% Funded internationally 27%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-18 Data: www.who.int/tb/data